KanitinibAlternative Names: CX1003
Latest Information Update: 14 Oct 2016
At a glance
- Originator KONRUNS Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Oct 2016 Preclinical trials in Solid tumours in China before October 2016 (PO)
- 04 Oct 2016 Konruns Pharmaceutical plans a phase I trial for Solid tumours in China (NCT02916095)